No Data
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $23
BofA Securities analyst Jason Zemansky maintains $Arcus Biosciences(RCUS.US)$ with a hold rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 61
Hold Rating on Arcus Biosciences Amid TIGIT Inhibitor Uncertainties
Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $25
Barclays analyst Peter Lawson maintains $Arcus Biosciences(RCUS.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.0% and
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Arcus up 4% Following Merck Welireg Kidney Cancer Data
Arcus Biosciences, Inc.'s (NYSE:RCUS) Business And Shares Still Trailing The Industry